ArticleThe Lancet regional health. Southeast Asia2026
Effectiveness of a trivalent inactivated split-virion influenza vaccine (Tri Fluvac) in Thailand: a phase IV test-negative case-control study.
Article in The Lancet regional health. Southeast Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thailand has invested in domestic influenza vaccine manufacturing to strengthen health security, yet real-world evidence on the effectiveness of locally produced vaccines is limited. This study aimed to evaluate the effectiveness of a domestically produced trivalent inactivated split-virion influenza vaccine (GPO Tri Fluvac) against medically attended outpatient laboratory-confirmed influenza infection following its introduction into the population. Methods: We conducted a phase IV test-negative case-control study among adults (≥18 years) presenting with influenza-like illness (ILI) in Lampang Province, Thailand, during the 2024-2025 influenza season. Laboratory-confirmed influenza was identified by RT-PCR. Vaccination status was obtained from hospital information system records. Vaccine effectiveness (VE) was estimated using multivariable logistic regression. Influenza virus clades and subclades were identified through viral genome sequencing. The study was registered in the Thai Clinical Trials Registry (TCTR20240909002). Findings: Among 4975 participants with ILI, 703 (14%) had laboratory-confirmed influenza. GPO Tri Fluvac vaccination was received by 103 (15%) of 703 influenza cases and 1611 (38%) of 4272 test-negative controls. The adjusted VE of GPO Tri Fluvac against medically attended outpatient laboratory-confirmed influenza was 73.1% (95% CI: 66.3-78.5). Subgroup VE estimates by age group and virus subtype were presented descriptively. VE against hospitalization could not be reliably estimated because of the small number of severe outcomes. Genome sequencing showed that most circulating viruses belonged to the same major clades as the corresponding Southern Hemisphere 2024 vaccine strains included in GPO Tri Fluvac. Interpretation: GPO Tri Fluvac provided substantial real-world protection against laboratory-confirmed influenza among adults in Thailand. These findings support its use in the national influenza vaccination program and highlight the value of domestic vaccine production for regional health security. Funding: Thailand Science Research and Innovation through the National Vaccine Institute and the Government Pharmaceutical Organization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.